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CYTOKINES and eicosanoid products of macrophages play
an essential role in expression of antitumour activity of
macrophages either in a cell-to-cell contact system be-
tween the effector and the target cell or as cell-free
soluble products. In this review the relationship between
three main monokines, namely TNF-, IL-1 and IL-6 and
the interrelationship between these monokines and eico-
sanoids (PGE2, PGI2, LTB4, LTC4) in their production and
in expression of antitumour activity is discussed. Empha-
sis is given to the effect of tumour burden on production
of the monokines and of the eicosanoids and on the
production of these compounds by the tumour cells.
Finally, the therapeutic implications drawn from animal
studies and clinical trials is discussed.
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Introduction
Since the pioneering work of Metchnikoff, it
became more and more evident that macrophage
cells play an essential role in a wide array of
biological activities. This includes among others the
events of nonspecific resistance against invasion of
foreign cells (including tumour cells), their function
as a crucial mediator in the development ofimmune
response and participation in the process of
inflammation (for review see Ref. 2).
The various functions of macrophages are
exerted either in a cell-to-cell contact set-up with
the target cells or by various biologically and
pharmacologically active factors released by these
cells. Among the most salient factors released by
macrophages are various monokines and products
of arachidonic acid (prostaglandins and leuko-
trienes).
An extensive amount of work has been done on
the pharmacological and biological effects of
macrophage cytokines and eicosanoids. The present
review is by no means intended to provide a full
coverage of all the activities of macrophage
cytokines and eicosanoids. The aim is to discuss
only the topic of interrelation between certain
macrophage cytokines and eicosanoids in the
context of their expression of antitumour activity.
The main emphasis will be on the role of
macrophage cytokines tumour necrosis factor-
(TNF-) interleukin-1 (IL-1) and interleukin-6
(IL-6) and on the role of prostaglandin E2 (PGE2),
leukotriene B4 (LTB4) and leukotriene C4 (LTC4)
and their interrelation in the production and
expression of antitumour activity. Another aspect
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to be discussed is the effect of tumour burden on
their production by macrophages, production of
these compounds by tumour cells and their
therapeutic effectiveness in experimental turnout
models and in cancer patients.
The first indications on induced release of certain
antitumour factors by bacteria-free filtrates came for
the early work of Coley (for review see Ref. 3).
Later on, Carswell et a].4 reported the occurrence
of an antiturnour cytotoxic factor in the serum of
mice which had undergone treatment with bacterial
lipopolysaccharide (LPS), coined the term tumour
necrosis factor (TNF) and suggested that TNF is
produced by activated macrophages in response to
LPS. The occurrence of a lymphocyte activated
factor produced by macrophages was first reported
in 19725,6 and was named lymphocyte activating
factor (LAF). In 1979, the nomenclature of various
cytokines was revised
7 and the former LAF was
given the name of IL-1 which is still used today.
IL-6 was initially described as a factor derived from
fibroblasts with antiviral activity.
8 The term IL-6
was first suggested by Poupart and colleagues
9 and
its production by human monocytes was reported.
1
Interactions in the production of
macrophage cytokines and
eicosanoids
Interactions in production between TNF-, IL-1 and IL-6:
It has been reported that production from blood
mononuclear cells and from peritoneal macro-
phages of TNF-, IL-1 and IL-6, can be
induced by the same stimulatory agents. This
applies to LPS,
>3 phytohaemagglutinin (PHA)
3
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and Staphylococcus epidermis.
13 It should be noted also monocytes was also reported by other authors.26 By
that the same monokine can be induced by different working with bone marrow derived mouse
mechanisms. Thus, itwas reported that Mycoplasma macrophages it was found that LPS induces
capricolum membranes induced TNF-o by a secretion of both TNF-oq IL-1 and IL-6.27 IL-1 was
mechanism different from induction by LPS. 14 able to stimulate IL-6 synthesis in human blood
In spite of the similarities in stimulation of monocytes but not in monocyte derived macro-
the production of the monokines, some differences phages whereas TNF-o had no effect on IL-6
were reported in the context of their production, synthesis in monocytes or macrophages.
28 Human
These differences indicate that mechanisms of their alveolar macrophages and blood monocytes pro-
production may be different. Thus, human duced large amounts of IL-6 in response to LPS
monocytes stimulated with pneumococcal cell and monocytes produced lesser amounts of IL-6 in
surface components produced IL-1 but not response to rIL-1.29 Monocytes aged in vitro
TNF-o.
15 Both protein kinase C (PKc) and produced little detectable IL-6 in response to LPS
calmodulin (CAM) kinase dependent pathways or rIL-1, which might suggest that release of IL-6
were found to be involved in the induction of under stimulus is correlated to the degree of
IL-1 mRNA by LPS, whereas TNF- expression maturity of macrophage cells.29 TNF-o or rIL-6
seemed to be PKc dependent but not CaM kinase itself did not modulate IL-6 production in human
dependent.
16 Other authors reported that TNF- peripheral blood mononuclear cells.
3 No evidence
and IL-1 production andsecretion by mononuclear was found that TNF-o acts to amplify the
phagocytes can be modulated differentially.
17 production of IL-6 or IL-1 by murine macrophage
Differences between the kinetics of production of cell lines.31 It was also claimed that synthesis and
IL-10, IL-lfl and TNF-o by murine peritoneal secretion of IL-1 either by human monocytes
32 or
macrophages during the peritoneal exudative by mouse bone marrow derived macrophages
33 are
response, were also described in relation to the two different biological events.
optimal culture conditions and sequence of Similarly, LPS-induced production of TNF-o34
appearance.
18 The production of TNF-o and IL-1 and IL-135 was also reported in human peritoneal
in alveolar human macrophages was found to be macrophages collected from patients on continuous
regulated differentially by LPS.9 A different pattern ambulatory peritoneal dialysis (CAPD) during an
of regulation was also observed in the case of episode of infectious peritonitis.
human macrophages: during the initial phase of The conclusion from the above-mentioned data
maturation of human blood monocytes (up to 7 is that TNF-oq IL-1 and IL-6 can mutually affect
days in culture), IL-lfl and IL-6 were down- their production. The production and release of
regulated whereas TNF-o levels markedly in- these cytokines are also affected by other agents
creased.2 A synergistic effect of interferon-z (including other cytokines) but these findings are
(IFN-z) and LPS was observed in relation to the beyond the scope of the present review. A
release of IL-lfl, IL-6 and TNF- from human schematic representation of the interrelationship
macrophages.eHowever, the LPS-inducedlevels of in production between the three cytokines is
these cytokines differed during prolonged cultiva- given in Fig. 1.
tion of macrophages (up to 28 days).
2 Differences
in levels of production of IL-loq IL-lfl and TNF-o
versus lower levels of IL-6 were also reported
following stimulation by various agents of human
blood mononuclear cells.
13
The relationship in production between TNF-o,
IL-lfl and IL-6 is expressed by the findings that
each one of these monokines can affect the
production of the other monokines. Thus TNF-o
was found to induce release of IL-1 in vilro2’22
and in vivo.23 TNF-o and IL-1 induced 1L-6
production in PiPo.
24 Stimulation of human mono-
cytes by IL-1 caused a rapid down-regulation of
IL-6 mRNA levels and concomitant enhancement
of IL-6 mRNA expression.
24 IL-6 itself was found
to suppress the IL-6-R at high concentrations.
25
IL-6 suppressed IL-lfl and TNF- production
induced by LPS or PHA in human blood
mononuclear cells.
13 Inhibition of tPS-induced
FIG. 1. Schematic representation of interrelationship in production by
macrophages between TNF, Ik-1 and IL-6. +" enhancement"
TNF production by IL-6 in cultured human inhibition.
LPS
TNFt
Stimulus r
IL-6
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Interactions in production between cytokines and eicosanoids A
series of findings indicated that production of
TNF- by macrophages can be regulated by both
endogenous and exogenous PGE2. Thus, in
response to LPS, murine peritoneal macrophages
release concomitantly increased amounts of TNF-
and PGE2 .36’37 However, addition of exogenous
PGE2 strongly suppressed the release of TNF- by
macrophages.36’37 PGE2 down-regulated the expres-
sion of TNF- gene in human blood monocytes.
38
In another work it was reported that low amounts
of PGE2 enhance release of TNF- from macro-
phages whereas high doses of PGE2 suppress its
release.
39 Some authors reported recently that the
gene expression of TNF- was enhanced by low
doses of PGE. and by cGMP, and suggested that
cGMP may represent one of the positive signals for
TNF- synthesis.
4
Suppression of LPS-induced TNF- production
by PGE. was also reported by other authors.41’42
The inhibitory effect ofPGE2 on TNF- production
was correlated with induced augmentation of
cAMP in macrophage cells. 36’39 In contrast to PGE.,
leukotrienes induce increases in TNF- release from
macrophages. Thus, human monocytes exposed to
graded concentrations of LTB4 release high
amounts of TNF-.
43 The enhancing effect of
leukotrienes on TNF-a may be related to increases
in cGMP levels by leukotrienes44 and is also
supported by findings that lipoxygenase inhibitors
suppress formation of TNF- in vitro and in vivo.45
Treatment of macrophages with LPS enhanced the
increase of a lipoxygenase product which counter-
acted the suppression of TNF- synthesis by a
lipoxygenase inhibitor when added to macrophages
exogenously.
46 Recent data suggest that en-
dogenous prostaglandins and leukotrienes do not
play a role in the regulation ofTNF- production.
47
In addition indomethacin (IND) (a cyclooxygenase
inhibitor), exogenous arachidonate and MK-886 (a
novel inhibitor of 5-1ipoxygenase product forma-
tion) do not affect TNF- production.
47 The
interrelationship between TNF- and PGE2 pro-
duction is also supported by the finding that TNF-
stimulates PGE2 production in murine resident
peritoneal macrophages.
22 Other data indicate that
enhancement ofTNF- activity may be independent
of PGE2 production. Thus IFN-y in combination
with LPS enhanced TNF- production but addition
of IFN-3 to LPS had no effect on PGE2 levels
produced in human monocytes.
48
With regard to IL-1, it was found that the same
stimulator, namely PHA, induced production of
both IL-1 and prostaglandin E in human monocyte
monolayers. Products of the cyclooxygenase
pathway of arachidonate metabolism seem not to
be involved in the mechanism by which IL-1
stimulates thymocyte proliferation, whereas pro-
ducts of the lipoxygenase pathway may mediate the
thymocyte proliferative response induced by IL-1.
Similarly, with TNF-, it seems that an ar-
achidonate lipoxygenase product is important in the
sequence of events leading to the production of
IL-1. Additionally lipoxygenase inhibitors affected
production of IL-1 in human peripheral blood
monocytes.
49 An enhancing role of leukotrienes in
production of IL-1 was also advocated by other
authors.5’5 Recently, it was reported that addition
of exogenous LTB4 to monocytes stimulates IL-1]
transcription and mRNA accumulation.
52 A self-
regulatory mechanism of IL-1 production was
suggested by data showing that exogenous IL-1
induces increases in the levels of PGE2 in murine
macrophage cultures, whereas exogenous PGE2 or
prostacyclin (PGI2) (measured as its stable metabo-
lite 6-keto prostaglandin F=) suppressed macro-
phage IL-1 production.
53 The inhibitory effect of
PGE2 was correlated to induce increases in cAMP
levels.
54 IL-1 was found, on the other hand, to
stimulate 5-1ipoxygenase activity and in this way
induces increases in PGE2 synthesis.
55 In contrast
to these data, it was also reported
56 that PGE. had
no effect on IL-1 synthesis in murine resident
peritoneal macrophages but rather had a direct
inhibitory effect on thymocyte proliferation.
5
In spite of the similarities in the stimulating
conditions for production ofTNF- and IL-1 some
differences were also reported. Thus, it was claimed
that PGE2 suppresses expression of cell-associated
TNF- in murine peritoneal macrophages but had
no effect on cell-associated IL-1 activity.
58 PGE2
suppressed accumulation of TNF mRNA but not
of IL-I and 1L-lfl mRNA accumulation. 58 The
conclusion from these experiments was that
synthesis of TNF appears to be regulated at the
level of transcription whereas synthesis ofIL-I and
IL-lfl is regulated post-transcriptionally.
58 Recent-
ly, it was shown that PGE2 inhibits release of
TNF- but not of IL-1/8 from human peritoneal
macrophages.
42 Interrelation between production of
prostaglandins and of IL-1/g in human peritoneal
macrophages was recently reexamined, s9 It was
found that PGI2 (measured as its stable metabolite
6-keto-PGF=) declined sharply during episodes of
peritonitis both in the presence or absence of LPS
in the culture medium of human peritoneal
macrophages.
59 On the other hand, PGE2 was
released in the same amounts in cultures of
macrophages collected during peritonitis and
during an infection-free period.
59 These results
suggest that PGI2 and PGE2 may play a different
role in the regulation of IL-lfl production by
human macrophages.
59
The production of IL-6 concomitantly to
production of PGE2 in LPS-stimulated rat Kupffer
cells was examined.
6 IL-6 production increased in
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FIG. 2. Schematic representation of interrelationship in production by
macrophages between cytokines (TNF, IL-1 and IL-6) and eicosanoids
(PGE2; LT: leukotrienes); +: enhancement; -: inhibition; *+ at low
doses, at high doses.
parallel with PGE2 before decreasing as PGE2
continued to rise.
6 Blocking of PGE2 production
by IND increased IL-6 levels significantly thus
showing that PGE2 produced by Kupffer cells
down-regulates IL-6 secretion.
6 However, cyclo-
oxygenase inhibitors inhibited production of IL-6
by human peripheral blood mononuclear cells,
61 but
no direct relationship between inhibition of IL-6
and production of PGE. was found.
61 Leukotrienes
stimulate production of IL-6 in cultures of human
monocytes.62’63 LTB4 stimulates production of IL-6
and induces accumulation of IL-6 mRNA.62’63
Finally, regarding the interrelation between the
production of IL-1 and PGE., it was reported that
IL-1 and PGE2 are produced by separate subsets of
human monocytes.
64 The interrelationship between
the production of cytokines and eicosanoids is
given in Fig. 2.
Effect of tumour burden on
production of macrophage
cytokines and eicosanoids
The functions of tumour associated macrophages
(TAM) have been investigated extensively (for
reviews see Refs. 65, 66). It was suggested that
in situ macrophages may affect the biology of
neoplastic tissues in various ways besides tumour
killing, by producing growth factors, by interaction
with haemostatic mechanisms, by release of
mutagenic reactive oxygen intermediates and
neutral proteinases, and by their capacity to induce
angiogenesis.
65
The effect of tumour burden on production of
macrophage cytokines and eicosanoids was ex-
amined in a series of experimental systems and in
cases of human cancer.
Experimental studies: It was reported that during
tumour growth in rats (subcutaneous implantation),
cyclooxygenase or thromboxane synthase is in-
hibited, whereas C5 and C12-1ipoxygenases of the
alveolar macrophages are activated. 67’68 A transient
increase of 12-HETE and LTC4 production in
murine peritoneal macrophages was also reported
in mice implanted subcutaneously with B16
melanoma cells.
69 Tumour-host derived macro-
phages were found to suppress a series of events
including activation ofT cells, natural killing (NK)
cells and lymphocyte activated killer (LAK) cells,
and generation of tumoricidal activity in normal
syngeneic murine splenic macrophages cultures in
the presence of LPS.7 The suppressive effects were
correlated with an increase in PGE2 secretion by
tumour-bearing host macrophages.
7
The role of prostaglandin secretion by macro-
phages from mice bearing syngeneic tumours was
also supported by other authors. Thus, splenic and
peritoneal macrophages collected from mice bear-
ing different syngeneic tumours secreted large
amounts of PGE2 as a result of their interaction
with the tumours.
71 These macrophages were
immunosuppressive and their suppressive activity
was significantly reduced by IND thus proving that
the suppressive effect was due to increased release
of prostaglandin.
71 In another study, it was shown
that inhibition of spleen cell cytotoxic capacity
toward murine Lewis carcinoma was due to an
increase in PGE2 levels.
72 The inhibitory effect was
prevented by pretreatment of tumour-bearing mice
with IND.
72
The effect of tumour burden on the ability of
macrophages to secrete cytokines was also ex-
amined. Continuous alveolar macrophage (AM) and
tumour infiltrated (TIM) cell lines were generated
from C57BL/6J mice and tested for their potential
to secrete IL-1, TNF- or IL-1 following exposure
to rMulFN-2 and LPS. 73 Neither cell line secreted
substantial amounts of IL-1 or TNF<z but secreted
large amounts of IL-6.
73 Peritoneal macrophages
from sarcoma-bearing mice produced progressively
less IL-1 as tumour burden increased.TM Administra-
tion of LPS to tumour-bearing mice early after
tumour transplantation, resulted in reduced tumour
growth and prevented the down-regulation of in
vitro IL-1 production by peritoneal macrophages.
TM
Thus, it seems that a specific defect in IL-1
production was associated with increasing tumour
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burden.TM In another study it was concluded that
murine tumour-infiltrating macrophages isolated
from the lungs of mice bearing lung B16F10
metastases responded as normal alveolar macro-
phages to biological response modifiers in relation
to induction of tumoricidal activity and to
secretion of IL-1 and TNF-. 75 However, tumour
associated macrophages (TAM) isolated from five
cases of murine sarcomas showed a limited capacity
to produce and release IL-1 as compared to
peritoneal macrophages upon stimulation with
LPS.
6
The role of TNF-z release by TAM in specific
defence against the inoculated tumour was
questioned by various authors. Thus TAM from
mice bearing EMT6 tumours exhibited high
anti-WEHI-164 activity77’78 due to release of
TNF-x
78 but was not effective against the EMT6
tumour. 77’78 Similarly, TAM in a murine fibrosarco-
ma model produced TNF-o but this production did
not affect the tumour growth.
79
Human studies: Indirect indication of the role of
prostaglandin production by macrophages from
cancer patients was provided by data showing that
monocyte-derived macrophages isolated from
blood of cancer patients can be rendered cytotoxic
by treatment with IND. 8’81 Apparently not all
macrophages collected from cancer patients could
be rendered cytotoxic against allogeneic or auto-
logous tumour target cells, presumably because
they were nonresponsive and/or because of the
presence of a plasma inhibitory factor. 81 In another
work, it was reported that peripheral and bone
marrow enriched fraction of monocytes produce
high levels of PGE2.
82 However, the increased
release of PGE2 was not correlated to clinical or
pathological findings.
82
The production of IL-1 and TNF-z by tumour-
associated mononuclear leukocytes (TAML) and
peripheral blood mononuclear leukocytes (PBML)
in cancer patients was determined. Stimulation by
LPS induced production of similar levels of TNF<z
in TAML and PBML but production of IL-1 was
markedly suppressed in LPS-stimulated tumour-
associated mononuclear leukocytes (TAML).
83 In
another study the release of IL-1 and IL-6 by TAM
from ascites and solid tumours of human ovarian
carcinoma was investigated. It was found that TAM
release spontaneously or upon LPS stimulation high
amounts of IL-6 whereas they were poor producers
of IL-1.84 LPS-induced production of TNF- by
peripheral blood macrophages was impaired in
cases of breast cancer.
85 On the other hand,
secretion of TNF- by monocytes from patients
with malignant brain tumours was significantly
greater by comparison with monocytes from
normal individuals.
6 Increase in secretion of
TNF- and of IL-1 was also reported by alveolar
macrophages from patients with lung cancer as
compared with secretion by peripheral blood
monocytes from the same patients or by alveolar
macrophages from patients with nonmalignant
disorders.
87 However, alveolar macrophages from
lung cancer patients were found to be impaired in
their ability to develop antitumour cytotoxic
activity compared with either the peripheral blood
monocytes from the same patients or alveolar
macrophages from patients with nonmalignant lung
disorders. 8v An increase in the level of TNF-o was
also found in tumour-infiltrating macrophages in
human colorectal adenocarcinoma. 88 The increase in
TNF-o levels correlated with an increase in the size
of the primary turnout.
88
Some work was dedicated to determining the
interrelationship between the production of TNF-o
and PGE2 by monocytes from cancer patients.
LPS-incubated monocytes from cancer patients
with malignancies of the digestive tract, produced
high levels of TNF-o and PGE2 when cultured in
medium with foetal bovine serum.
89 Addition of
cancer-patient plasma to the medium suppressed
markedly TNF production but induced a prominent
enhancement of PGE2 production.
89 Plasma of
cancer patients did not exhibit TNF-o activity but
such plasma contained increased levels of PGE2 .89
However, although low amounts of exogenous
PGE2 suppressed TNF-o production by normal
monocytes, addition of 10% plasma-containing
PGE2 did not induce suppression of TNF-o
production, thus indicating that some unidentified
factor(s) in the plasma of cancer patients modulates
the TNF-o and PGE2 production in these patients.
89
Correlation between production of TNF-o and
PGE2 by peripheral blood monocytes was also
studied in patients with bladder cancer. It was
found that these patients had either higher TNF-o
production or higher PGE2 production.
9 A shift in
macrophage population was due to turnout growth
in BALB/c mice" immunosuppression in the
tumour-bearing host was caused at least in part to
the inability of Mac-1 + and/or Mac-3 + to control
production of PGE2 by Mac-2+ macrophages.
91
Certain tumour-cell membrane constituents were
found to activate human monocytes for TNF-o
synthesis.
92
In view of the wide variation in the results on
release of macrophage cytokines and prostaglandin
by monocyte-macrophages and turnout-associated
macrophages from cancer patients, it still seems
difficult to draw final conclusions on the role of this
release in clinical settings of neoplasia. It seems that
increased release of PGE2 is usually found in TAM
and may be correlated to an increase in the severity
of the disease. Thus, high prostaglandin production
in tissues surrounding human breast turnouts is
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correlated with high metastatic potential for
neoplastic cells.93 Successful therapy with IND and
with a combination ofIND and IL-2 was explained
by abrogation of prostaglandin-mediated suppres-
sion of NK activity and IL-2 production.
94-97
Production of eicosanoids and
cytokines by tumour cells
In view of the role played by eicosanoids and
cytokines in expression of antitumour activity it
seems likely that intrinsic production of these
compounds by tumour cells may affect the
resistance to tumour development in turnout-
bearing animals and in human neoplasia.
First reports indicated that BP8/P1 murine ascitic
tumour and, to a less extent a subcutaneously
implanted S180 rat tumour, produced PGE2 .98
However, the role of PGE2 production in the
development of the tumour remains uncertain
because induction of a decrease in PGE2 levels by
IND did not affect appreciably the tumour
growth.
98 In more recent work it was shown that
certain murine tumours produce prostaglandins and
that their response to IND therapy was directly
related to their ability to produce prostaglandin.
99
Production of PGE2 by EL4 leukaemia cells from
C57BL/6 mice was also correlated to the extent of
100 migration and dissemination of the tumour.
Prostaglandin biosynthesis was also found to occur
in established cell lines derived from human lung,
colorectal adenocarcinoma, and ovarian adeno-
carcinoma,lm A difference in the amount of PGE2
released was found between cancer cells meta-
stasizing into rat liver or rat kidney.
1 It was
assumed that this difference may be related to the
mechanism of cancer metastases or to selection of
102 the organ in which metastases occur.
Tumour cells were reported to also produce
cytokines. Thus, tumours from cachectic mice
produced both TNF- and IL-1 in vivo as
documented by the presence of TNF- and IL-I
103 mRNA and immune-reactive protein for IL-I.
The tumour cells also produced TNF- and IL-I
in long-term cultures but not IL-6.13 Secretion of
TNF-0 by human leukaemic cells was also
reported.
14 A myeloma cell line established from
the pleural effusion of a myeloma patient secreted
both TNF- and IL-6 and these cytokines induced
proliferation of the cell line.
15 In IL-6 production
a dual effect was described: the murine MH134
tumour cells produced high amounts of IL-6
whereas the murine CSAIM tumour produced only
marginal levels of IL-6.6 However, both tumours
induced production of IL-6 by T cells in the
tumour-bearing host.6 Leukaemic cells from
patients with acute myeloid leukaemia produced
both IL-6 and IL-1.
7 Prostatic carcinoma cell lines
expressed the IL-6 receptor and secreted IL-6.18
Squamous cell carcinoma cell lines produced both
IL-1 and IL-6.9
An interesting situation was described with the
murine P815 mastocytoma: this line produces
TNF1 but, at the same time, this was one of the
first tumour cell lines which was found to be
sensitive to exogenous TNF. 3’4
It seems likely that production of prostaglandins
and macrophage cytokines as well as induction of
their production by macrophages in tumour-
bearing hosts plays a role in the development of the
tumour in vivo. However, the direct relationship
between neoplasia and the ability of tumour cells to
produce and/or induce production of macrophage
eicosanoids and cytokines is not clear yet.
Interactions between macrophage
cytokines and eicosanoids in
expression of antitumour activity
Interactions between TNF-, IL-1 and IL-6: TNF-
alone is cytostatic or cytotoxic for a wide range
of murine and human tumour-cell lines.11’12 Oi1
the other hand, TNF had no effect on a wide
variety of murine and human tumour-cell lines
and enhanced the growth of various normal cell
lines. 111’112 Moreover, a heterogeneous cytotoxic
response of TNF-0 was described for various cell
lines isolated from the same single neoplasm of
human colorectal carcinoma113 or renal cell
carcinoma.
114 Membrane-associated TNF was
shown to be the lytic principle of activated
macrophages cytotoxic for TNF susceptible tumour
cells.
115 The complexity ofTNF antitumour activity
is also shown by findings that TNF- mediates the
enhanced cytotoxicity induced in monocytes by
IFN, IL-1 and by TNF itself.
16 Treatment of
human monocytes with TNF- increased their
cytostatic ability in a dose-dependent manner
against P815 murine mastocytomas.
1 IL-1 was also
reported to be cytocidal for several tumour-cell
lines. 118 However, IL-1 can act also as an autocrine
growth factor for acute myeloid leukaemia cells.
19
The fact that TNF- and IL-1 are both
produced by activated macrophages, and that
TNF- itself is an inducer of IL-1 production,
prompted investigations devised to determine
possible synergistic and additive antitumour effects
of combinations of the two cytokines. Combination
of TNF- and IL-1 synergistically
12 or in additive
manner1 inhibited the growth of human A-375
melanoma cells. In another study, it was claimed
that enhancement of antitumour human monocyte
activity by combined TNF- and IL-1/ was less
than additive.12 We found that a combination of
TNF- and IL-1 had an additive effect on
antitumour cytostasis against WEHI-3B murine
300 Mediators of Inflammation-Vol 1992Monokines, eicosanoids and antitumour activity
tumour cells.
123 It should be noted that TNF-o and
IL-1 represent only a fraction of a wider spectrum
of macrophage cytokines involved in expression of
antitumour activity of macrophages. 124’125
Antitumour activity of IL-6 against human
breast carcinoma and leukaemia/lymphoma cell
lines
126 and in vivo against four murine metastatic
tumours
12v has been reported. On the other hand,
autocrine generation and requirement as a growth
factor for human multiple myelomas
128 and for
human renal cell carcinomas
129 has also been
described.
IL-6 production is induced by LPS which also
stimulates production of TNF- and IL-1, IL-1
induced synthesis of IL-6 in human blood
monocytes28’29 and TNF- induced IL-6 in sera of
cancer patients and turnout-bearing mice.13 More-
over, it was found that IL-6 is involved in
IL-1 induced activities as pyrogenicity and
stimulation of thymocyte proliferation.
TM However,
there are apparently few data on synergistic,
additive or antagonistic effects of combination of
IL-6 with either TNF- or IL-1 on tumour cells. It
was claimed that systemic administration of low
doses of IL-6 in combination with sub-therapeutic
doses of TNF to mice bearing a weakly
immunogenic syngeneic tumour resulted in marked
127 regression and some cure.
Interactions between cytokines and eicosanoids: Modulation
of production of various arachidonic acid deriva-
tives is by itself related to induction of antitumour
activity in macrophages. Thus, in vitro treatment of
murine peritoneal macrophages with IND, a
cyclooxygenase inhibitor, induced antitumour cyto-
static activity against a murine plasmacytoma and
this effect was increased when LTB4 was added to
the cultures. 132’13 The IND stimulation of macro-
phage cytostasis against the murine plasmacytoma
was enhanced by endogenous metabolites of
lipoxygenase and counteracted by PGE2 .14 Induc-
tion of macrophage cytostasis towards P815
mastocytoma by calcium ionophore was reversed
by specific inhibition of lipoxygenase.
15 In other
work it was shown that LTC4 is an essential
5-1ipoxygenase intermediate in A23187-induced
antitumour cytostatic activity
16 and that addition
of L-serine to cultures stimulated by calcium
ionophore increased both the accumulation ofLTC4
in murine macrophages as well as their antitumour
activity.
13v LPS-induction of macrophage tumour
killing was counteracted by PGE2 but not by
PGI1.138
It should be noted that there are contradictory
reports concerning the effect of prostaglandin
production by macrophages turnout cells, and the
direct effect of prostaglandins on turnout growth.
Thus, it was reported that PGE could inhibit DNA
synthesis and tumour cell replication in vitro and
tumour growth in vivo.19’14 PGA also inhibited
turnout growth in vitro and in vivo. 141’142 However,
in spite of the fact that induction of antitumour
activity in macrophages by LPS was associated with
an increase in PGE2 and thromboxane production,
these compounds did not seem essential for the
expression of antitumour activity, as induction of
antitumour activity took place and was even
enhanced in the presence of indomethacin.14 It has
been reported also that addition ofexogenous PGE2
to murine peritoneal macrophages did not alter the
ability of these cells to produce high levels of
tumour-cell lysis when stimulated with LPS. 144
Finally, contrary to suggestions in Refs. 143
and 144 blockade of prostaglandin synthesis by
indomethacin prevented the effect of LPS and led
to a substantial resumption of target growth in the
presence of activated macrophages.
14s A differential
effect of PGE2 on expression of macrophage
antitumour activity was described in relation to the
state of the macrophages: culture conditions that
caused increased PGE2 production by activated
macrophages resulted in inhibition of their
tumoricidal activity but production of high levels
of PGE2 by resident and peptone elicited
macrophages was associated with an increase in
antitumour activity.
146
The contradictory results described may be due
to differences in sources of macrophages, in types
of target tumour cells and in the physiological state
of the effector cells.
We and others have investigated the interrelation
between eicosanoids and TNF- or IL-1/ in
expression of antitumour activity. Human peri-
toneal macrophages collected from CAPD patients
during an intercurrent infectious inflammation
showed a sharp drop in cAMP and a decrease in
production of cyclooxygenase metabolites.
147 On
the other hand, they were primed in an in vivo
inflammatory environment so that they were much
more cytostatic against murine tumour ceils than
macrophages collected during inflammation free
periods.
148 When macrophages collected during
inflammation were cultured with LPS, their
antitumour cytostasis against two murine tumour-
cell lines was markedly increased and this increase
was associated with increase in TNF-o and IL-lfl
release.34,35,148
Interrelation between eicosanoids and TNF- or
IL-lfl in expression of antitumour activity was also
examined by addition of the cell-free compounds to
cultures of turnout cells. Interestingly, concomitant
addition ofPGE2 enhanced the antitumour effect of
IL-1]3 on a IL-lfl susceptible WEHI-3B murine
turnout, whereas addition of LTC4 inhibited the
antitumour effect of IL-1.149 The synergistic effect
between prostaglandins and cytokines in expression
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of antitumour activity was also observed when the
WEHI-3B murine tumour cells were first treated
with the cytokine and afterwards with the
prostaglandin: pretreatment with IL-lfl rendered
the tumour cells susceptible to PGE2 or PGI2
whereas only susceptibility to PGE2 was increased
by pretreatment with TNF-.
123 Other authors
found that Kupffer resident rat cells and Kupffer
inflammatory murine liver cells produced both
TNF- and PGE2. Upon activation with IFN-y +
LPS (for mouse resident Kupffer cells) or with LPS
alone (for rat Kupffer cells and mouse inflammatory
Kupffer cells) the cells produced more PGE2 and
more TNF-o.
15 However, PGE2 did not play a role
in tumour because treatment with indomethacin
increased the TNF induced killing,
is
Therapeutic implications
Work on therapeutic effectiveness was mostly
concentrated on ways to affect in vivo prostaglandin
production and on the possibility of using TNF-
either alone or in combination with other agents
for therapy. The therapeutic effectiveness was
examined in three systems: against animal tumours,
against xenogeneic transplants of human tumours
in nude mice and in clinical trials in cancer patients.
Experimental animal tumours Prostaglandins have been
implicated as enhancers of tumour growth and
spread.93’151 The sources of prostaglandin were
tumour cells
99 and/or cells of monocyte-macro-
phage lineage. Accordingly, it was assumed that
inhibition of prostaglandin biosynthesis by cyclo-
oxygenase inhibitors might have a beneficial
therapeutic effect.
Most of the work on the basis of this assumption
was done by looking on the therapeutic effect of
the cyclooxygenase inhibitor IND as downgrading
PGE2 production. Thus, it was shown that IND
therapy prevents tumour metastasis of a mouse
mammary carcinoma94 cures B16F10 murine
melanoma lung metastasis when given in combina-
tion with IL-2,
95 and cures murine Ehrlich ascites
tumours when administered in combination with
LAK cells and IL-2.
96 The effectiveness of IND
therapy was correlated to the ability of murine
tumours to produce prostaglandin.
99 However, it
was doubted if the therapeutic effectiveness of
indomethacin is due to inhibition of PGE2
production.
152 IND treatment prolonged survival of
sarcoma-bearing mice without, however, having an
effect on serum concentrations of IL-6 which
increased progressively with increase of the
153 turnout.
Tumour necrosis-like activities have been de-
scribed since the initial observations in the 1890s
on regression of tumours in patients with
concomitant bacterial infections or injected with
bacterial culture filtrates (for review see Ref. 3).
After its first characterization as tumour necrosis
factor produced by macrophages,
4 its activity
against a long series of human and murine tumours
was demonstrated in vitro.’2 The next obvious
step was to determine the therapeutic effectiveness
ofTNF- in tumour-bearing hosts, rHuTNF- was
shown to be effective against subcutaneously
implanted murine MethA sarcoma but not against
the same tumour injected i.p.
54 The curative effect
ofTNF-0 was attributed to its ability to induce local
haemorrhages because of its effect on the
endothelial cells.54 It should be noted also that
TNF-0 therapy involved generation of specific
cell-mediated antitumour immunity by a still
undefined mechanism.
154
In another experimental system the antitumour
effect of recombinant murine TNF- given either
by continuous i.v. infusion or by repeated i.v.
injections was determined in a rat liver metastases
model.
155 Only early continuous infusion had an
effect on the number of liver metastases presumably
because higher doses of TNF-0 were tolerated by
this schedule.
155 The conclusion of the authors was
that TNF- by itself is not a very efficient
antitumour agent and it might be necessary to use
TNF-0 in combination with other antitumour
agents.
155 A similar conclusion of more
therapeutic effectiveness of TNF in combination
with other treatments was in the case of TNF
radiotherapy by comparison with TNF-0 alone in
rat renal-cell carcinoma,
56 or a combination of
TNF- with the interferon-inducer bropirimine in
rat colon cancer.57 Sequential use of anti-CD3, IL-2
and TNF for LAK induction and maintenance
potentiated antitumour activity against a pulmonary
metastatic model in mice. 158
Another interesting additive effect was described
after combined treatment with activated macro-
phages and a low dose of TNF-0 in mice bearing
Lewis lung carcinoma or EMT6 sarcoma.
159 A
synergistic therapeutic effect was also described in
tumour-bearing mice treated with low doses of IL-6
in combination with subtherapeutic doses of
TNF-0. 127 The therapeutic use of TNF-0 in
tumour-bearing mice was found to be affected by
an increase in the toxicity of TNF- in tumour-
bearing hosts
6 and by induction of tolerance to
TNF-0.
16 A side effect of antibodies to TNF- was
reported" passive immunization with anti-TNF
antibodies abrogated part.ially IL-2 toxicity in
tumour-bearing mice.
162 Finally, the effect of TNF
therapy might differ in context to the strain of mice"
the curative effect of TNF was stronger against
MethA sarcomas implanted in BALB/c nu/+ mice
than into BALB/c nu/nu mice, when TNF was
injected i.v. and similar when injected i.t.
63 A new
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therapeutic approach was described recently: a
novel chimera tumour necrosis factor (TNF-STt)
constructed by connecting a modified recombinant
human TNF-o (rTNF-S) with thymosin-/g4 was
suggested to be a promising approach for obtaining
molecules that more favourably attack tumours
than conventional rTNF.164
Xenografts of human tumours in nude mice: TNF was also
found to be effective against human malignant
melanoma, human gastric cancer and nasophar-
yngeal carcinoma cell lines implanted in nude
mice.
16 Combined therapy with IFN-, and TNF-o
was found to be more effective than TNF-ot alone
against human ovarian cancer cells inoculated in
nude mice.
165 A similar synergistic effect between
IFN (interferon-alpha) and TNF-o was described
against a human tumour line causing lung
metastasis and intra-abdominal carcinomatosis in
nude mice.
166 In another study it was found that
combined treatment with TNF-o and etoposide was
efficient against a human renal cell carcinoma
implanted in athymic mice.
16v
Clinical trials: The findings on cytotoxic effects of
cytokines (especially TNF-) on a wide array of
murine and human turnout cell lines in vitro and the
results on therapeutic effectiveness against murine
turnouts and against human turnout cells implanted
in nude mice prompted the start of clinical trials in
various cancer patients. Unfortunately the results in
clinical trials were not very spectacular. In one of
the first studies a certain improvement due to
TNF-o therapy was observed in three out of 18
patients: two cases of lymphoma and one case of
Hodgkin’$.168 Febrile reactions and other side effects
occurred in most of the patients and they could be
prevented by steroids and IND.
168 However,
according to the authors, "such prophylaxis may
not be desirable because its influence on possible
therapeutic benefits is unknown". Some beneficial
response in cases of gastric cancer and non-
Hodgkin’s lymphoma were also reported by other
authors.
169 Side effects to TNF-o were recorded and
could be ameliorated by IND or ketoprofen.
169 In
cases of B-lymphoma some improvement was
detected in one out of 26 patients and side effects
to TNF- were again observed,iv In another study
no antitumour response was detected in 29 cancer
patients,
lvl In two cases out of 16 evaluable patients
with disseminated cancer, TNF-0 therapy had some
antitumour effect: regression of a neck lesion in one
case and resolution of malignant ascites in
another, iv2 The results on various clinical trials with
TNF-0 until 1988 were summarized at a seminar of
the 19th German Cancer Congress: "Although
TNF as a single agent is unlikely to be of major
benefit for patients with cancer, it has to be
concluded that the great expectations which were
particularly due to its dramatic effect in the murine
sarcoma model leading to the designation ’TNF’
have been disappointed",
lv
More clinical trials have been performed with
TNF-0 in recent years. In a phase II trial with 22
eligible patients with metastatic colorectal adeno-
carcinoma, treatment with TNF- was not
effective.
1v4 A more promising result was obtained
in a clinical trial with TNF-0 including 29 patients
with refractory malignant ascites: out of 29 patients,
22 responded with a complete (16) or partial (6)
resolution of their ,ascites. lvs Recently, in one out
of 53 patients with advanced malignancies a partial
response to TNF was observed in one patient with
colorectal carcinoma, lv6 In another recent study no
clinical efficacy of TNF-0 was found in a phase I
trial with patients with advanced cancer, lvv Rather
disappointing results concerning the use of human
recombinant TNF-0 for cancer therapy were
reported recently by two groups: no objective
responses were observed in 22 cases of advanced
carcinoma of the pancreas
iv8 and no significant
antitumour activity of rHTNF-0 was detected in
127 eligible patients with diverse metastatic
malignancies,
iv9 Another group concluded that
rHTNF-0 has only modest antitumour activity in
26 patients with renal cell carcinoma.
18
A more promising approach for therapy was
suggested by using TNF-0 in combination with
other interleukins. 81’182 This was suggested by
results obtained in vitro and in experimental systems
in vivo with such combinations. However, in only
one patient with melanoma and one patient with
mesothelioma (out of 36 patients), was some
response observed to combined treatment of
recombinant TNF- with recombinant IFN-2,18
and two partial responses were seen in a study with
combined recombinant IL-2 followed by re-
combinant TNF therapy in 31 patients with
metastatic malignancies.
84
The use of TNF-0 therapy is handicapped by the
toxicity of the agent and by its extremely pleiotropic
biological effects. It should be also noted that in
most clinical trails with TNF-0 most of the patients
were found refractory to other kinds of treatments
and were in an advanced stage of disease. Moreover,
it was reported that sera of cancer patients may
contain factor(s) inhibiting TNF.18’86 It has been
also reported that treatment with TNF-0 might
induce decreases of NK cell activity and of
monocyte production in cancer patients.
8v
The general conclusion from clinical trials until
now is that therapy with TNF- is still in its infancy.
Apparently, combinations of various interleukins
for cancer therapy might be more promising. A new
approach was suggested in the recent years
consisting of therapy by monocytes from cancer
patients induced to maturate in vitro to macrophages
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FIG. 3. Negative and positive aspects of the TNF anticancer therapy.
possessing antitumour cytotoxic activity, a88’189 In
view of the findings that such macrophages secret
various cytokines,
2 it might be that the activated
macrophages continue to secrete in vivo inter-
leukins cytotoxic for cancer cells.
Concluding Remarks
A vaste amount of material has accumulated on
the interrelationship in production between macro-
phages cytokines, macrophage cytokines and
eicosanoids, production of these products by
turnout cells and the effect of tumour burden on
their production. The expression of interrelation-
ship between macrophage cytokines themselves and
between macrophage cytokines and eicosanoids was
also extremely investigated. In certain instances the
results obtained in in vitro systems were also
expressed in vivo in various therapeutic schedules in
mice bearing syngeneic tumours on xenografts of
human turnout-cell lines. Unfortunately, the pro-
mising results obtained in vitro and in experimental
systems in vivo have not yet been well duplicated in
clinical trials. Much more work has still to be done
in defining optimal conditions for the use of single
interleukins and (more likely) combinations of
interleukins for effective anticancer therapy. Some
of the negative and positive aspects of use of one
of the most commonly tested cytokine (TNF-0 is
schematically represented in Fig. 3). It is also
possible that other approaches such as therapy with
cells able to produce in vivo a wide array of cytokines
(macrophages) or devising ways for effective
induction of cytotoxic interleukins in vivo by a
cancer patient’s own cells might lead to more
promising results.
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